Xlife Sciences AG / Key word(s): Alliance/Partnership
Strategic Collaboration Between Xlife Sciences AG, Huraypositive Corp., and OncoMASTER Inc. to Boost Digital Health and Precision Oncology in Asia
16.06.2025 / 16:00 CET/CEST

Zurich, 16th of June 2025: Xlife Sciences AG («Xlife Sciences»SIX: XLS), a Swiss-based incubator and accelerator for life sciences innovation, has entered into a Memorandum of Understanding (MoU) with Korea’s leading digital health pioneer, Huraypositive Corp. («Huraypositive»), and AI-powered oncology innovator, OncoMASTER Inc. («OncoMASTER»). This strategic agreement aims to foster a dynamic partnership in the fields of digital health and precision oncology, leveraging complementary strengths to drive clinical innovation and global reach.

The MoU was formally signed at a joint ceremony in Seoul by Oliver R. Baumann, Chief Executive Officer and Member of the Board of Directors of Xlife Sciences AG, Dooah Choi, CEO of Huraypositive Corp., and Woo Young Jang, CEO of OncoMASTER Inc.

The collaboration focuses on three key pillars:

• Expansion into Asia: Xlife Sciences will utilize Huraypositive’s extensive healthcare ecosystem and OncoMASTER’s domain expertise in AI-driven oncology to extend its footprint across Asian markets.
• 
  
• Innovation Acceleration: The parties will co-develop transformative healthcare platforms that integrate AI, digital health, and clinical insights to advance personalized care.
• 
  
• Global Market Access: Huraypositive and OncoMASTER will benefit from Xlife Sciences’ academic and industrial network to explore commercialization opportunities in Europe.

This trilateral initiative marks a decisive step toward the globalization of the Xlife Sciences model, aiming to bridge academic innovation with clinical translation in Asia and beyond - while also enabling the transfer of promising innovations from Korea to Europe. It also reflects a mutual commitment to deliver novel, data-driven solutions for unmet medical needs through a collaborative ecosystem.

Oliver R. Baumann, CEO of Xlife Sciences, stated: «We are proud to enter this strategic alliance with Huraypositive and OncoMASTER, two forward-thinking leaders in digital health and precision oncology. This partnership underscores our commitment to expand internationally while accelerating development cycles through synergistic collaborations. We are confident this will contribute to a robust innovation pipeline and elevate patient-centric technologies across borders.»

Dooah Choi, CEO of Huraypositive, commented: «As a pioneer in digital health in Korea, Huraypositive is excited to collaborate with global innovation leaders like Xlife Sciences and OncoMASTER. By combining our digital health expertise with cutting-edge AI and precision health technologies, we aim to help shape a more connected, personalized healthcare ecosystem across Asia.»

Woo Young Jang, CEO of OncoMASTER, added: «Through this collaboration, we aim to expand the global reach of our AI-based models for cancer treatment prediction and bring data-driven precision oncology to broader patient populations. We also look forward to enabling new translational pathways with the support of Xlife’s network.»

This agreement serves as a foundation for future joint initiatives and reflects a shared vision to redefine how healthcare innovation is developed and deployed across continents.

Financial calendar

Contact
Information for investors and journalists: Xlife Sciences AG, Dr. Dennis Fink, dennis.fink@xlifesciences.ch

Xlife Sciences AG, 
Talacker 35, 
8001 Zurich, 
Switzerland,
Phone +41 44 385 84 60
info@xlifesciences.ch, www.xlifesciences.ch, 
Commercial Register Zurich CHE-330.279.788 
Stock Exchange: SIX Swiss Exchange

About Xlife Sciences AG (SIX:XLS) 

Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development, and participates in their subsequent performance. For more information, visit https://www.xlifesciences.ch

About Huraypositive

Huraypositive is a pioneering digital health company based in Korea, recognized for introducing the country’s first digital chronic disease management solutions. With over 15 years of experience, Huraypositive collaborates with national health institutions and major corporate partners to advance personalized healthcare. By integrating artificial intelligence into its digital platforms, the company is redefining patient engagement and enabling smarter, more proactive health management across diverse populations. For more information, visit https://www.huray.net

About OncoMASTER

OncoMASTER is a precision oncology company at the forefront of transforming cancer treatment through advanced artificial intelligence and multi-omics technologies. Leveraging clinical and molecular data from more than 10,000 advanced cancer patients—the largest such dataset in Asia - OncoMASTER develops predictive algorithms to guide personalized treatment decisions. Its data-driven approach is setting new standards in oncology, accelerating the transition from generalized therapies to individualized cancer care. For more information, visit https://www.onco-master.com/main/company

Disclaimer 

Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements. 

End of Media Release